Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 546

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 546
---
, the Company amended and restated the Note with Iris (the “Amended Note”). The Amended Note increased the principal amount from $1.5 million to $2.5 million.

On March 6, 2024, the Company borrowed an additional $0.3 million from Prophase.

On March 9, 2024, the Company entered into a third amendment to the Business Combination Agreement extending the outside date to July 31, 2024.

On April 2, 2024, the Company funded an additional advance under the Amended Note of $0.3 million.

On May 1, 2024, the Company borrowed an additional $0.1 million from Prophase.

On May 7, 2024, the Company funded an additional advance under the Amended Note of $0.03 million.

On May 13, 2024, the Company borrowed an additional $0.2 million from Prophase, and funded an additional advance under the Amended Note of $0.2 million.

<div align='center'>F-85</div>

TABLE OF CONTENTS

#### Annex A​

### BUSINESS COMBINATION AGREEMENT
<div align='center'>by and among</div>

#### IRIS ACQUISITION CORP,

#### IRIS PARENT HOLDING CORP.,

#### SPAC MERGER SUB, INC.,

#### LIMINATUS PHARMA MERGER SUB, INC.
<div align='center'>and</div>

#### LIMINATUS PHARMA, LLC

#### DATED AS OF NOVEMBER 30, 2022
TABLE OF CONTENTS

Table of Contents

| ​ | ARTICLE I CERTAIN DEFINITIONS                                                             | ​ | ​ | ​ | ​ | A-2  | ​ | ​ |
| ​ | ​                                                                                         
 Section 1.1                                                                               
 Certain Definitions                                                                       
 ​                                                                                         | ​ | ​ | ​ | ​ | A-2  | ​ | ​ |
| ​ | ARTICLE II MERGERS                                                                        | ​ | ​ | ​ | ​ | A-15 | ​ | ​ |
| ​ | ​                                                                                         
 Section 2.1                                                                               
 Company Merger                                                                            
 ​                                                                                         | ​ | ​ | ​ | ​ | A-15 | ​ | ​ |
| ​ | ​                                                                                         
 Section 2.2                                                                               
 SPAC Merger                                                                               
 ​                                                                                         | ​ | ​ | ​ | ​ | A-15 | ​ | ​ |
| ​